Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT02779751
- Locations
- 🇫🇷
Hôpital Arnaud de Villeneuve - CHU Montpellier, Montpellier, Hérault, France
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Colorado School of Medicine, Aurora, Colorado, United States
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 463
- Registration Number
- NCT02763566
- Locations
- 🇧🇷
Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil
🇨🇳Jilin Province Tumor Hospital, Chang Chun, Ji Lin, China
🇨🇳Liaoning Cancer Hospital&Institute, Shenyang, Liaoning, China
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 234
- Registration Number
- NCT02747004
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇦🇷Clinica Viedma, Viedma, Río Negro, Argentina
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT02745769
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇬🇧For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Conditions
- Interventions
- Drug: SunitinibDrug: Trastuzumab and PertuzumabDrug: Vemurafenib and CobimetinibDrug: PalbociclibDrug: Nivolumab and IpilimumabDrug: AbemaciclibDrug: Atezolizumab and PHESGODrug: Atezolizumab and TalazoparibDrug: Tucatinib plus Trastuzumab Subcutaneous (SC)Drug: FutibatinibDrug: TalazoparibDrug: TemsirolimusDrug: RegorafenibDrug: OlaparibDrug: PembrolizumabDrug: EntrectinibDrug: Larotrectinib
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- American Society of Clinical Oncology
- Target Recruit Count
- 3791
- Registration Number
- NCT02693535
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States
🇺🇸Sutter Auburn, Auburn, California, United States
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT02688088
- Locations
- 🇺🇸
University of Kansas Hospital, Fairway, Kansas, United States
🇺🇸South Texas Accelerated Research Therapeutics, LCC, San Antonio, Texas, United States
🇺🇸Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
A Study of Abemaciclib in Healthy Participants
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT02677844
- Locations
- 🇺🇸
Covance Clinical Research Unit, Evansville, Indiana, United States
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 237
- Registration Number
- NCT02675231
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Northwest Medical Specialties, PLLC, Puyallup, Washington, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 53
- Registration Number
- NCT02644460
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Conditions
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 124
- Registration Number
- NCT02523014
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Breast, Grosse Pointe Woods, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.